DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Barber-Say syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBarber-Say syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for barber-say syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glycoprotein Ib platelet subunit alpha (GP1BA) — GP1BA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cacdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4C2A · 2.081 Å · ligand CACODYLATE ION (CAC). Experimental structure, not a prediction.
What the evidence adds up to
Barber-Say syndrome is a rare congenital disorder with fewer than 20 reported cases as of 2019. It is caused by mutations in the TWIST2 gene and appears to follow autosomal dominant inheritance, as shown by a father-to-daughter transmission in which the father had a milder phenotype. The core features, described across multiple case reports, include severe generalised hypertrichosis, macrostomia, ocular telecanthus or hypertelorism, a bulbous nose, atrophic or redundant skin, ectropion, and hypoplastic nipples or mammary glands. One 14-year-old girl also had ablepharon, helix agenesis of both ears, and a distinctive dermatoglyphic pattern. A 7-year-old girl examined at a dental school presented with macrostomia, broad alveolar ridges, gingival fibromatosis, taurodontism, delayed tooth eruption, and malocclusion; her dental treatment included gingivoplasty and orthodontics. A one-day-old female had a senile skin appearance, low hairline, coarse face, thin upper lip, and one area of mild skin atrophy.
Affected individuals have otherwise normal cognition and physical functioning, but the unusual facial morphology causes psychosocial consequences. A 2017 study that included personal testimonies from a parent and an affected adult woman focused on perception of illness, body satisfaction, and the impact on quality of life. The authors stressed that management must address both physical appearance and the psychosocial effects of the condition. No drug treatments for the syndrome itself are mentioned in any of these reports; management is described as requiring a multidisciplinary approach, and dental care may involve surgery and orthodontics.
What is missing is any clinical trial or systematic treatment protocol for Barber-Say syndrome. There are no data on drug repurposing, no molecular pathway interventions tested in patients, and no studies that stratify patients by mutation type or severity. The literature consists entirely of case reports and one psychosocial survey. Funding for natural history studies, development of patient-reported outcome measures, and any interventional trial design would be needed before treatment efficacy could be assessed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2010 · 22 citations
Barber–Say syndrome in a father and daughter
AbstractWe report on a father to daughter transmission of Barber-Say syndrome (BSS), a rare, congenital disorder characterized by severe generalized hypertrichosis, macrostomia, ocular telecanthus, bulbous nose and atrophic skin. These two cases further support the autosomal dominant inheritance. Both presented with the typical BSS symptoms but the phenotypic expression in the father was milder. Treatment is challenging for both patients and doctors, requiring a multidisciplinary approach.
American Journal of Medical Genetics Part A · 2009 · 17 citations · open access
Case report supporting that the Barber–Say and ablepharon macrostomia syndromes could represent one disorder
AbstractWe report on a 7-year-old girl with unequivocal features of Barber-Say syndrome (BSS): generalized hypertrichosis especially at the back, dry lax skin, macrostomia, thin lips, cup-shaped ears, bulbous nose, hypoplastic nipples, and abnormal external genitalia. She also demonstrated conductive hearing impairment and microblepharon. BSS has been reported with ectropion (not present in our patient), but ablepharon and microblepharon (i.e., absent or hypoplastic eyelids) have always been considered as hallmarks of ablepharon macrostomia syndrome (AMS). This is the first report of microblepharon in BSS. Other authors have discussed that BSS and AMS could possibly represent one syndrome, and our report supports this hypothesis.
American Journal of Medical Genetics Part A · 2010 · 16 citations
Oral and dental abnormalities in Barber–Say syndrome
AbstractA previously unreported case of Barber-Say syndrome is described with special attention to dental manifestations. A 7-year-old female with multiple congenital anomalies such mammary gland hypoplasia, hypertrichosis, ectropion, and redundant skin was seen at the School of Dentistry of the University of São Paulo. Oral examination revealed macrostomia, broad alveolar ridges, gingival fibromatosis, taurodontism, delayed tooth eruption, and malocclusion. Dental treatment included gingivoplasty and orthodontic treatment.
Molecular Syndromology · 2017 · 8 citations · open access
Barber-Say Syndrome and Ablepharon-Macrostomia Syndrome: A Patient's View
Abstractgene. Both are characterized by abnormalities in ectoderm-derived structures and cause a very unusual morphology of mainly the face in individuals with otherwise normal cognition and normal physical functioning. We studied the impact that the presence of BSS and AMS has on psychosocial functioning of affected individuals and their families, using their point of view to start with. We tabulated frequently asked questions from affected individuals and families, and a parent of an affected child and an affected adult woman offered personal testimonies. We focused on perception of illness, body satisfaction, and the consequences for an otherwise normal individual who has a disorder that interferes with body image. The importance of paying particular attention to the management of both the physical appearance and the consequences of these entities on the quality of life is stressed by the affected individuals themselves.
Genetics and Molecular Biology · 2000 · 5 citations · open access
Barber-Say syndrome: further delineation of the clinical spectrum
AbstractWe report on a 14-year-old girl who presented a multiple congenital anomaly pattern: ablepharon, hypertelorism, telecanthus, macrostomia, helix agenesis of both ears, redundant thick skin and severe hirsutism, the 5th reported case of Barber-Say syndrome. Our patient had almost the same phenotype as that of the patient cited by Martínez Santana et al. (Am. J. Med. Genet. 47: 20-23, 1993) including the same until then undescribed dermatoglyphic pattern.
Indian Dermatology Online Journal · 2019 · 0 citations · open access
Barber Say Syndrome (A new case report)
AbstractBarber Say syndrome (BSS) is a rare ectodermal dysplasia with neonatal onset characterized by congenital generalized hypertrichosis, atrophic skin, ectropion and macrostomia. A literature review showed less than 20 previously reported cases of Barber Say syndrome. This presentation reports a one day old female with syndrome face, low hairline, coarse face, macrostomia, thin upper lip, bilateral ectropion and hypertelorism, hypertrichosis, senile skin appearance, hypoplastic nipples and one area of mild skin atrophy. These findings are consistent with BSS.
Supplementary Material for: Barber-Say Syndrome and Ablepharon-Macrostomia Syndrome: A Patient's View
AbstractBarber-Say syndrome (BSS) and ablepharon-macrostomia syndrome (AMS) are infrequently reported congenital malformation disorders caused by mutations in the <i>TWIST2</i> gene. Both are characterized by abnormalities in ectoderm-derived structures and cause a very unusual morphology of mainly the face in individuals with otherwise normal cognition and normal physical functioning. We studied the impact that the presence of BSS and AMS has on psychosocial functioning of affected individuals and their families, using their point of view to start with. We tabulated frequently asked questions from affected individuals and families, and a parent of an affected child and an affected adult woman offered personal testimonies. We focused on perception of illness, body satisfaction, and the consequences for an otherwise normal individual who has a disorder that interferes with body image. The importance of paying particular attention to the management of both the physical appearance and the consequences of these entities on the quality of life is stressed by the affected individuals themselves.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
